Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:
“August is Head and Neck Cancer Awareness Month – a time that always brings me back to the purpose behind our work. These cancers remain among the most challenging solid tumors, and progress has historically been slow.
But this year, the momentum feels different. The recent amivantamab publication in Journal of Clinical Oncology exploring its potential in head and neck cancer is a powerful reminder of what can happen when scientific imagination meets disciplined execution.
As we look ahead to ESMO in October, I’m energized by the data we’ll be sharing across our solid‑tumor portfolio. These readouts reflect years of thoughtful clinical design, modality innovation, and a commitment to pushing into spaces where patients urgently need new options. It’s an exciting moment – not because the science is advancing on its own, but because teams are willing it forward.
And that’s where I want to pause.
None of this happens without extraordinary people. Camille Hertzka, Parthiv Mahadevia, Eric Wong, Mahadi Baig, Amy McCarte-Roshak, Kiran Patel and Joshua Bauml have each brought exceptional scientific leadership, clarity, and drive to our programs. Their work embodies what makes Johnson and Johnson Innovative Medicine special: rigor paired with creativity, urgency paired with compassion, and an unwavering focus on the patients who inspire every step we take.
Grateful for the progress we’re making, grounded in the purpose of this awareness month, and inspired by the people who turn possibility into progress.”
Other articles featuring Mark Wildgust on OncoDaily.